Pharma stock engaged in the business of manufacturing and exporting APIs, Intermediates, and formulations jumped upto 16 percent in the day’s trade upon posting its Q4FY24 results with a 1,130 percent jump in Net Profits.
With a market capitalization of Rs. 702 Crores, the shares of IND Swift Laboratories were trading at Rs. 118.70, up 13 percent from its previous day’s close price of Rs. 105.20.
Its revenue from operations grew by 29 percent YoY from Rs. 304.24 Crores in Q4FY23 to Rs. 393.33 Crores in Q4FY24 and it grew by 37 percent QoQ from Rs. 287.51 Crores in Q3FY24 to Rs. 393.33 Crores in Q4FY24. Annually it generated a revenue of Rs. 1,207.31 Crores in FY23 and Rs.1,280.89 Crores in FY24 indicating a growth of 6 percent YoY.
Its Net Profit grew by 1,130 percent QoQ from Rs. 19.41 Crores in Q3FY24 to Rs. 238.82 Crores in Q4FY24 and it generated a profit of Rs. 238.82 Crores in Q4FY24 from a loss of Rs. 25.12 in Q4FY23. Annually it generated a profit of Rs. 47.59 Crores in FY23 and Rs. 420.96 Crores in FY24 indicating a growth of 785 percent YoY.
Ind Swift Laboratories Limited is engaged in the business of manufacturing and exporting APIs, Intermediates, and formulations. It caters to the API needs of regulated markets including USFDA, EDQM, PMDA, ANVISA, EU-GMP, KFDA, NMO, and many others.
It manufactures APIs for Cardiovascular health, Antihistamine, Antidiabetic, Parkinson’s Disease, Antineoplastic, Antipsychotic, Antimigraine, ADHD Symptoms, Analgesics, Alcohol Abstinence and many more.
Written by Bharath KS
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
